Skip to main content

August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology

The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies

James T. Kenney, RPh, MBA

Leukemia, Oncology

Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia

Leukemia, Oncology

CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies

Breast Cancer, Oncology

Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence

Multiple Myeloma, Oncology

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy

Multiple Myeloma, Oncology

Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma

Gene-Expression Signature Validated as Prognostic Marker in Stage II Colon Cancer

Melanoma, Oncology

Combination Immunotherapy Makes Progress in Advanced Melanoma

A New Paradigm Matching Targeted Therapy to Molecular Alterations Independent of Tumor Type

Page 1 of 4
Results 1 - 10 of 32